# Autonomous Agentic Midday Decision — 2026-08-19

- Timestamp: 2026-08-19 16:02 UTC / 12:02 ET
- Account: Robinhood Agentic ••••1041 (433711041)
- Mode: Pre-authorized autonomous equities-only operation
- Policy: `playbook/autonomous-policy.md` ACTIVE; no date-specific trading plan found.

## Broker and kill-switch verification

- Account active, cash account, `agentic_allowed=true`; no other account touched.
- Account value: $329.18 (above $10 kill switch)
- Equity value: $259.39; cash/buying power: $69.79; unsettled funds: $0
- Open-ish equity orders queried separately: new, queued, confirmed, unconfirmed, partially_filled — all empty.
- Filled equity orders created today: none.
- Pending-order commitment: $0.00; liquid buying power after pending orders: $69.79.
- 80% deployable slice: $55.83; required 20% reserve: $13.96.
- Existing gross equity deployment: 78.80% of account value. No broker/tool uncertainty observed. No new order placed because no fresh candidate passed the confirmed-entry and non-extension gates.

## Holdings and management

Quotes as of approximately 16:01 UTC.

### MA — HOLD (score 13/16)
- 0.113541 shares; average $572.48; price $577.84; value ~$65.61; unrealized +$0.61 (+0.94%).
- Daily: prior close $574.31, SMA20 $561.94, SMA50 $532.52, 20d +6.69%, 60d +14.95%, ATR14 $10.94. Above rising trend averages and outperforming SPY over 20/60 days.
- Intraday: +0.61% vs prior close, but faded from $582.93 morning high to ~$577.84. Support $570–574; invalidation/management stop $564; targets $594 then $602.
- Fundamentals: Q2 revenue $9.277B, net income $4.388B, margin 47.3%; EPS $5.04 vs $4.76 estimate. High-quality profitable catalyst profile.

### SHOP — HOLD (score 13/16)
- 0.862075 shares; average $144.09; price $148.06; value ~$127.63; unrealized +$3.42 (+2.75%).
- Daily: prior close $146.58, SMA20 $135.98, SMA50 $124.30, 20d +19.14%, 60d +39.79%, ATR14 $7.77. Strongest held momentum and clear SPY outperformance.
- Intraday: +1.01%; held above the open after testing $149.78. Support $145.90 then $142; invalidation/management stop $140; targets $158.87 then $166.
- Fundamentals: Q2 revenue $3.583B; net income $1.502B; EPS $0.42 vs $0.37 estimate. Valuation is rich (PE ~98.9), so trend discipline remains essential.

### BAC — HOLD / weakest holding (score 11/16)
- 1.046363 shares; average $62.12; price $63.26; value ~$66.19; unrealized +$1.19 (+1.83%).
- Daily: prior close $64.23, SMA20 $62.93, SMA50 $60.04, 20d +4.92%, 60d +24.74%, ATR14 $0.95. Longer trend remains constructive.
- Intraday: -1.52%, declining from $64.43 to the $63.12 low while XLF was roughly flat; sector-relative weakness makes BAC the weakest holding.
- Support $63.00/$62.90; invalidation/management stop $61.90; targets $65.23 then $67.00.
- Fundamentals: Q2 revenue $31.558B, net income $9.074B, EPS $1.21 vs $1.11 estimate; valuation moderate at ~14.8x earnings. Hold only while $62.90–$61.90 support remains intact.

Estimated aggregate risk to stated management stops: MA ~$1.57, SHOP ~$6.80, BAC ~$1.42, total ~$9.79. This exceeds the default $6 target, but reflects existing written stop distances rather than a new risk increase; no stop was widened and no new risk was added.

## Regime

- Mixed/rotation: SPY +0.43%, QQQ +0.10%, IWM +0.70%; SPY and IWM are above SMA20/SMA50, while QQQ is above SMA20 but slightly below SMA50. XLY +1.90% led; XLF -0.10% lagged.
- Macro backdrop remains earnings-positive but narrow, with sticky inflation/energy and Fed/Jackson Hole sensitivity. This supports selective longs and retests, not broad gap chasing.

## Ranked fresh opportunities

1. **EL — 11/16, WATCH/RETEST**: +16.60% post-earnings, ~3.0x typical full-day volume by midday, holding near $98 after a $99.82 high. Prior daily SMA20/50 were ~$85.04/$84.18 and ATR14 ~$2.34; current price is roughly 5.6 ATR above SMA20, far too extended. Wait for a multi-session base or orderly retest near $94–96. Negative trailing PE and recovery execution risk reduce quality.
2. **TEM — 10/16, WATCH/RETEST**: +20.06%, 10.15M shares vs ~4.94M average full-day volume, and improving intraday structure after an early shakeout. Still unprofitable and current price is above the prior 20-day high; verified catalyst quality was insufficient for an extended entry. Wait for $55–57 support/retest.
3. **TWST — 10/16, WATCH**: +17.50%, prior 20d +21.11% and 60d +97.33%, with raised revenue guidance and 23% YoY revenue growth. Price faded from $141.10 to ~$136.42; very extended and unprofitable. Wait for consolidation/retest around $128–132.
4. **MRNA — 9/16, NO TRADE**: verified late-stage melanoma vaccine success is materially positive, but +127.6% intraday with a $114.46–$163.47 range is a disqualifying extension and reversal risk. No chase.
5. **BNTX — 9/16, NO TRADE**: +20.24% sympathy/catalyst move, but unprofitable and faded from $116 to ~$111.52. No clean retest.

MRVI and DNA were rejected despite gains because they are speculative/loss-making with weaker daily structures and insufficient verified direct catalyst quality. LZB and BLZE were downside movers, not long setups.

## Decision and actions

- **Action: HOLD MA, SHOP, BAC; no add, trim, exit, or rotation at midday.**
- **Orders reviewed/placed:** none. Review tool was not called because no candidate passed the strategy gate; broker review success would not cure an extended entry.
- **Deployment:** existing equities 78.80% of account value; cash 21.20%. Of current $69.79 liquid balance, $55.83 is policy-target deployable and $13.96 reserved, but the deployable slice remains idle because all leading fresh setups were extended or lacked a sufficiently verified entry/catalyst. Reserve was preserved.
- Next management triggers: exit/reassess BAC on a decisive break below $62.90 and no recovery; SHOP below $140; MA below $564. Do not widen stops or average down.
